Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: A cross-sectional analysis

Infection

Volumn 40, Issue 3, 2012, Pages 311-318

  Sterrantino, G ^a   Zaccarelli, M ^b   Colao, G ^c   Baldanti, F ^d   Di Giambenedetto, S ^e   Carli, T ^f   Maggiolo, F ^g   Zazzi, M ^h  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c Azienda Ospedaliera Universitaria   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f Ospedale di Grosseto   (Italy)

^g Divisione Malattie Infettive Ospedale di Bergamo   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

Author keywords

Darunavir; Genotypic resistance; Protease inhibitors; Ritonavir boosted darunavir

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ISOLEUCINE; PROLINE; PROTEINASE; PROTEINASE INHIBITOR; THREONINE; VALINE;

ANTIVIRAL RESISTANCE; ARTICLE; CROSS-SECTIONAL STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; SULFONAMIDES; TIME FACTORS; TREATMENT FAILURE;

EID: 84864286386     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0237-y     Document Type: Article

References (34)

1. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Béthune MP. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005; 49:2314-21.
2. Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008;10:131-42.
3. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81: 13845-51.
4. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PIresistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3123-9.
5. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol. 2004;338:341-52.
6. King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol. 2004;11:1333-8.
7. Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem. 2005;48: 1813-22.
8. Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. Infection. 2009;37:233-43.
9. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69: 477-503.
10. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-88.
11. De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 2009;23:1829-40.
12. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-78.
13. De Meyer S, Hill A, De Baere I, Rimsky L, Azijn H, Van Baelen B, De Paepe E, Vangeneugden T, Lefebvre E, De Béthune MP. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI 2006), Denver, CO, USA, 5-8 February 2006 Abstract 157.
14. Llibre JM, Puig T, Liu TF, Martinez-Picado J, Santos JR, Bravo I, Shafer RW, Schapiro JM, Clotet B. Predicted resistance to tipranavir and darunavir in clinical samples from 1999-2006 with protease resistance mutations. In: Proceedings of the 11th European AIDS Conference/EACS, Madrid, Spain, 24-27 October 2007. Abstract P3.4/05.
15. Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother. 2009;63:585-92.
16. Moltó J, Santos JR, Pérez-Alvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52:3928-32.
17. Delaugerre C, Mathez D, Peytavin G, Berthé H, Long K, Galperine T, de Truchis P. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS. 2007;21:1210-3.
18. Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, Vangeneugden T, Miralles D, Meyer SD, Parys W, Lefebvre E; TMC114-C208 Study Group; TMC114-C215 Study Group. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24-31.
19. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58.
20. Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E, Spinosa-Guzman S. ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected adults. In: Proceedings of the 10th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010. J Int AIDS Soc. 2010;13:P3.
21. Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS 139 TRIO Trial study group. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS. 2010;24:2651-6.
22. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18:156-63.
23. Young J, Scherrer AU, Günthard HF, Opravil M, Yerly S, Böni J, Rickenbach M, Fux CA, Cavassini M, Bernasconi E, Vernazza P, Hirschel B, Battegay M, Bucher HC; Swiss HIV Cohort Study. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Med. 2011;12: 299-307.
24. Stanford University, HIV Drug Resistance Database. http://hivdb. stanford.edu/.
25. Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004;9:465-78.
26. de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, Lefebvre E, de Béthune MP. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379-88.
27. Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D; ANRS Co3 Aquitaine Cohort. Virological response to darunavir/ritonavir-based regimens in antiretroviralexperienced patients (PREDIZISTA study). Antivir Ther. 2008; 13:271-9.
28. Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother. 2008;52:491-6.
29. De Meyer S, Dierynck I, Lathouwers E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Peeters M, Picchio G, de Béthune MP. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2. In: Proceedings of the XVIIth International HIV Drug Resistance Workshop, Sitges, Spain, 10-14 June 2008. Antivir Ther 2008;13(Suppl 3):A33 (abs 31).
30. Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Dominguez S, Mortier E, Molina JM, de Truchis P. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS. 2008;22: 1809-13.
31. Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS. 2007;21: 2033-42.
32. Garrido C, Poveda E, Corral A, de Mendoza C, Soriano V. Low rate of tipranavir and darunavir resistance mutations in PI-experienced patients using the new interpretation scores-implications for PI sequencing. In: Proceedings of the XVIIth International HIV Drug Resistance Workshop, Sitges, Spain, 10-14 June 2008. Antivir Ther 2008;13(Suppl 3):A107 (abs 97).
33. Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885-8.
34. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010;54:2473-9.